Symptoms such as forgetfulness, loss of concentration and disorientation can be early signs of dementia or Alzheimer’s disease (AD).
A new study by Georgetown University done on nicotinamide adenine diclonucleotide (NADH), a coenzyme found in all living cells, revealed that a “significant number of patients with CFS showed marked improvement.” The double-blind clinical trial began in April 1996 and is ongoing.
Click this link to view the entire study: Down Syndrome and Alzheimers The reduction of NADH ubiquinone oxidoreductase 24- and 75-kDa subunits in brains of patients with Down syndrome and Alzheimer’s disease.
NEW FOLLOW-UP STUDY SHOWS THAT A NATURALLY OCCURRING COENZYME NUTRITIONAL SUPPLEMENT ENADA® NADH CLINICALLY DEMONSTRATES BENEFITS FOR ALZHEIMER’S PATIENTS To read the study please click this link : Nov 2002 ICMAN Study on Alzheimers 2nd International Conference on Mechanisms and Actions of Nutraceuticals October 6 -9, 2002 Krems/Danube AUSTRIA November 19, 2002 Contact: Matt Fitzsimmons USA, Tel: 212 736-1039 email@example.com or Vida Demarin MD, Tel: 38513768282 firstname.lastname@example.org NEW FOLLOW-UP STUDY SHOWS THAT A NATURALLY OCCURRING COENZYME NUTRITIONAL SUPPLEMENT ENADA® NADH CLINICALLY DEMONSTRATES BENEFITS FOR ALZHEIMER’S PATIENTS Vienna, Austria (11/02) – At the 2nd International Conference on Mechanisms and Actions of Nutraceuticals (ICMAN) the findings of a study conducted by an international team of medical researchers under the direction of Professor V.
Objective: To evaluate the effect of stabilized oral NADH (reduced nicotinamide adenine dinucleotide; ENADA®) on cognitive functioning in patients with AD.
Summary: This study was designed to evaluate the effect of stabilized oral reduced nicotinam,de adenine din ucleotide (NADH) on cognitive functioning in patients with Alzheimer’s dsease (AD).
Although significant progress has been achieved in revealing the etiology of AD, the search for efficient therapy stays the man goal.